Stryker Co. (NYSE:SYK) Shares Bought by First National Trust Co

First National Trust Co boosted its stake in shares of Stryker Co. (NYSE:SYK) by 169.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 9,380 shares of the medical technology company’s stock after purchasing an additional 5,900 shares during the period. First National Trust Co’s holdings in Stryker were worth $2,809,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of Stryker by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 30,665,520 shares of the medical technology company’s stock valued at $8,379,967,000 after acquiring an additional 143,631 shares during the period. FMR LLC grew its position in shares of Stryker by 2.5% during the 3rd quarter. FMR LLC now owns 5,972,582 shares of the medical technology company’s stock valued at $1,632,127,000 after acquiring an additional 144,208 shares during the period. Morgan Stanley grew its position in shares of Stryker by 4.4% during the 3rd quarter. Morgan Stanley now owns 5,315,227 shares of the medical technology company’s stock valued at $1,452,493,000 after acquiring an additional 223,728 shares during the period. Fisher Asset Management LLC grew its position in shares of Stryker by 2.6% during the 4th quarter. Fisher Asset Management LLC now owns 4,042,317 shares of the medical technology company’s stock valued at $1,210,512,000 after acquiring an additional 103,326 shares during the period. Finally, Northern Trust Corp grew its position in shares of Stryker by 3.9% during the 3rd quarter. Northern Trust Corp now owns 3,505,595 shares of the medical technology company’s stock valued at $957,974,000 after acquiring an additional 131,590 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the transaction, the director now owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Up 0.6 %

Shares of SYK stock traded up $1.82 during trading on Friday, hitting $328.45. 1,589,424 shares of the stock traded hands, compared to its average volume of 1,415,127. The firm has a market capitalization of $125.12 billion, a P/E ratio of 37.49, a price-to-earnings-growth ratio of 2.55 and a beta of 0.91. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.71 and a quick ratio of 0.97. The firm’s fifty day moving average price is $346.99 and its 200-day moving average price is $317.29. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.36 by $0.14. The firm had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.14 EPS. As a group, research analysts forecast that Stryker Co. will post 11.94 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 0.97%. The ex-dividend date was Wednesday, March 27th. Stryker’s payout ratio is presently 36.53%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Barclays raised their target price on Stryker from $372.00 to $376.00 and gave the company an “overweight” rating in a research report on Thursday. BTIG Research raised their price target on shares of Stryker from $366.00 to $369.00 and gave the company a “buy” rating in a research note on Wednesday. Evercore ISI raised their price target on shares of Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Robert W. Baird raised their price target on shares of Stryker from $367.00 to $378.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, UBS Group raised their price target on shares of Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a research note on Wednesday. Four analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $365.94.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.